370 related articles for article (PubMed ID: 25102404)
1. The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease.
Zhang C; Zheng X; Wan X; Shao X; Liu Q; Zhang Z; Zhang Q
J Control Release; 2014 Oct; 192():317-24. PubMed ID: 25102404
[TBL] [Abstract][Full Text] [Related]
2. Dual-functional nanoparticles for precise drug delivery to Alzheimer's disease lesions: Targeting mechanisms, pharmacodynamics and safety.
Zheng X; Zhang C; Guo Q; Wan X; Shao X; Liu Q; Zhang Q
Int J Pharm; 2017 Jun; 525(1):237-248. PubMed ID: 28432017
[TBL] [Abstract][Full Text] [Related]
3. Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer's Disease.
Zheng X; Shao X; Zhang C; Tan Y; Liu Q; Wan X; Zhang Q; Xu S; Jiang X
Pharm Res; 2015 Dec; 32(12):3837-49. PubMed ID: 26113236
[TBL] [Abstract][Full Text] [Related]
4. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease.
Zhang C; Chen J; Feng C; Shao X; Liu Q; Zhang Q; Pang Z; Jiang X
Int J Pharm; 2014 Jan; 461(1-2):192-202. PubMed ID: 24300213
[TBL] [Abstract][Full Text] [Related]
5. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice.
Zhang C; Wan X; Zheng X; Shao X; Liu Q; Zhang Q; Qian Y
Biomaterials; 2014 Jan; 35(1):456-65. PubMed ID: 24099709
[TBL] [Abstract][Full Text] [Related]
6. [Effects of β-sheet breaker peptide H102 on synaptic plasticity associated proteins in double transgenic AD mice].
Yuan XY; Wang C; Sun FX; Xu SM
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2016 Apr; 32(4):293-298. PubMed ID: 29931950
[TBL] [Abstract][Full Text] [Related]
7. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.
Liu Z; Jiang M; Kang T; Miao D; Gu G; Song Q; Yao L; Hu Q; Tu Y; Pang Z; Chen H; Jiang X; Gao X; Chen J
Biomaterials; 2013 May; 34(15):3870-81. PubMed ID: 23453061
[TBL] [Abstract][Full Text] [Related]
8. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma.
Zhang B; Sun X; Mei H; Wang Y; Liao Z; Chen J; Zhang Q; Hu Y; Pang Z; Jiang X
Biomaterials; 2013 Dec; 34(36):9171-82. PubMed ID: 24008043
[TBL] [Abstract][Full Text] [Related]
9. Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides.
Li J; Zhang C; Li J; Fan L; Jiang X; Chen J; Pang Z; Zhang Q
Pharm Res; 2013 Jul; 30(7):1813-23. PubMed ID: 23549751
[TBL] [Abstract][Full Text] [Related]
10. In vivo Evaluation and Alzheimer's Disease Treatment Outcome of siRNA Loaded Dual Targeting Drug Delivery System.
Zhang C; Gu Z; Shen L; Liu X; Lin H
Curr Pharm Biotechnol; 2019; 20(1):56-62. PubMed ID: 30727887
[TBL] [Abstract][Full Text] [Related]
11. Brain-neuron targeted nanoparticles for peptide synergy therapy at dual-target of Alzheimer's disease.
Guo Q; Li Y; Xu S; Wang P; Qian K; Yang P; Sheng D; Wang L; Cheng Y; Meng R; Cao J; Luo H; Wei Y; Zhang Q
J Control Release; 2023 Mar; 355():604-621. PubMed ID: 36738970
[TBL] [Abstract][Full Text] [Related]
12. Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice.
Liu Y; An S; Li J; Kuang Y; He X; Guo Y; Ma H; Zhang Y; Ji B; Jiang C
Biomaterials; 2016 Feb; 80():33-45. PubMed ID: 26706474
[TBL] [Abstract][Full Text] [Related]
13. Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma.
Xin H; Jiang X; Gu J; Sha X; Chen L; Law K; Chen Y; Wang X; Jiang Y; Fang X
Biomaterials; 2011 Jun; 32(18):4293-305. PubMed ID: 21427009
[TBL] [Abstract][Full Text] [Related]
14. B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide.
Liu Z; Gao X; Kang T; Jiang M; Miao D; Gu G; Hu Q; Song Q; Yao L; Tu Y; Chen H; Jiang X; Chen J
Bioconjug Chem; 2013 Jun; 24(6):997-1007. PubMed ID: 23718945
[TBL] [Abstract][Full Text] [Related]
15. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization.
Sánchez-López E; Ettcheto M; Egea MA; Espina M; Cano A; Calpena AC; Camins A; Carmona N; Silva AM; Souto EB; García ML
J Nanobiotechnology; 2018 Mar; 16(1):32. PubMed ID: 29587747
[TBL] [Abstract][Full Text] [Related]
16. Neurotherapeutic applications of nanoparticles in Alzheimer's disease.
Sahni JK; Doggui S; Ali J; Baboota S; Dao L; Ramassamy C
J Control Release; 2011 Jun; 152(2):208-31. PubMed ID: 21134407
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer's disease.
Lauzon MA; Daviau A; Marcos B; Faucheux N
J Control Release; 2015 May; 206():187-205. PubMed ID: 25804873
[TBL] [Abstract][Full Text] [Related]
18. [The effects of H102 on NF-κB signal pathway in brain of transgenic AD mice].
Wang C; Yuan XY; Sun FX; Jiang F; Xu SM
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2016 Mar; 32(3):193-197. PubMed ID: 29931875
[TBL] [Abstract][Full Text] [Related]
19. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.
Kulkarni PV; Roney CA; Antich PP; Bonte FJ; Raghu AV; Aminabhavi TM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(1):35-47. PubMed ID: 20049829
[TBL] [Abstract][Full Text] [Related]
20. Novel piperine-loaded Tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer's disease: pharmaceutical, biological, and toxicological studies.
Elnaggar YS; Etman SM; Abdelmonsif DA; Abdallah OY
Int J Nanomedicine; 2015; 10():5459-73. PubMed ID: 26346130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
